Scott M. Thacher

Orphagen Pharmaceuticals (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index1.9kcitations51works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Retinoids in leukemia and cellular processes(15), Skin and Cellular Biology Research(13), Estrogen and related hormone effects(11), Psoriasis: Treatment and Pathogenesis(7), Blood properties and coagulation(6)

Publications51 total

A potent and selective RORγ inhibitor for the treatment of autoimmune diseases
Bioorganic & Medicinal Chemistry Letters·2025
A Concise and Modular Approach to Generate Novel RORγ Agonists
Journal of Medicinal Chemistry·2025· 1 cited
Discovery and characterization of OR-449, a potent antagonist to steroidogenic factor-1 (SF-1) and clinical candidate for treatment of ACC
Endocrine Abstracts·2025Open Access
Pharmacological Properties of JTE-151; A Novel Orally Available RORγ Antagonist That Suppresses Th17 Cell-Related Responses <i>in Vitro</i> and <i>in Vivo</i>
Biological and Pharmaceutical Bulletin·2024· 4 citedOpen Access
Discovery and SAR of JTE-151: A Novel RORγ Inhibitor for Clinical Development
Journal of Medicinal Chemistry·2024· 5 citedOpen Access
RF07 | PSUN355 Downstream Targets of the Steroidogenic Factor-1 (SF-1) Antagonist OR-449 in PDX Models of ACC
Journal of the Endocrine Society·2022Open Access
Abstract LB144: Antagonism of SF-1 as a potential targeted therapy for malignant Leydig cell tumors
Cancer Research·2022
A Novel Steroidogenic Factor-1 Antagonist, OR-449, as a Targeted Therapy for Adrenocortical Cancer
Journal of the Endocrine Society·2021Open Access
SUN-LB23 Translational Feasibility of Steroidogenic Factor-1 Antagonists as a Novel Targeted Therapy for Adrenocortical Cancer
Journal of the Endocrine Society·2020Open Access
Discovery of Second Generation RORγ Inhibitors Composed of an Azole Scaffold
Journal of Medicinal Chemistry·2019· 31 citedOpen Access
Ternary crystal structure of human RORγ ligand-binding-domain, an inhibitor and corepressor peptide provides a new insight into corepressor interaction
Scientific Reports·2018· 18 citedOpen Access
Ternary complex of human <scp>ROR</scp>γ ligand‐binding domain, inverse agonist and <scp>SMRT</scp> peptide shows a unique mechanism of corepressor recruitment
Genes to Cells·2017· 27 citedOpen Access
SAR Exploration Guided by LE and Fsp <sup>3</sup> : Discovery of a Selective and Orally Efficacious RORγ Inhibitor
ACS Medicinal Chemistry Letters·2015· 58 citedOpen Access
Potent, Selective and Cell Penetrant Inhibitors of SF-1 by Functional Ultra-High-Throughput Screening
Molecular Pharmacology·2008· 47 cited
Retinoid X receptor agonist elevation of serum triglycerides in rats by potentiation of retinoic acid receptor agonist induction or by action as single agents 2 2Abbreviations: RARs, retinoic acid receptors; and RXRs, retinoid X receptors.
Biochemical Pharmacology·2001· 33 cited
Enantioselective Syntheses of Potent Retinoid X Receptor Ligands:  Differential Biological Activities of Individual Antipodes
Journal of Medicinal Chemistry·2001· 77 citedOpen Access
ChemInform Abstract: New Dermatological Agents for the Treatment of Psoriasis
ChemInform·2001
New Dermatological Agents for the Treatment of Psoriasis
Journal of Medicinal Chemistry·2001· 40 citedOpen Access
CCDC 161829: Experimental Crystal Structure Determination
The Cambridge Structural Database·2001Open Access
Therapeutic Applications for Ligands of Retinoid Receptors
Current Pharmaceutical Design·2000· 132 cited
page 1 of 3Next →

Frequent Co-authors

Roshantha A.S. Chandraratna(14), Hai‐Yan Tao(12), Paul D. Crowe(9), Yoshiaki Katsuda(7), Tsuyoshi Adachi(7), Makoto Shiozaki(7), Akihiro Nomura(6), Robert H. Rice(5), Kazuyuki Hirata(5), Masayuki Kotoku(5), Takayuki Yamaguchi(5), Kojo Arita(5), Masato Noguchi(5), Vidyasagar Vuligonda(4), Katsuya Maeda(4), Shintaro Hirashima(4), Naoki Miyagawa(4), Kota Asahina(4), Satoki Doi(4), Morgan Fenn(4)